<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ppharm</journal-id><journal-title-group><journal-title xml:lang="ru">Педиатрическая фармакология</journal-title><trans-title-group xml:lang="en"><trans-title>Pediatric pharmacology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1727-5776</issn><issn pub-type="epub">2500-3089</issn><publisher><publisher-name>Издательство «ПедиатрЪ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15690/pf.v22i2.2881</article-id><article-id custom-type="elpub" pub-id-type="custom">ppharm-2597</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ  СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL  ARTICLES</subject></subj-group></article-categories><title-group><article-title>Клинико-эпидемиологическая характеристика склеродермии у детей Самарской области: одномоментное ретроспективное исследование</article-title><trans-title-group xml:lang="en"><trans-title>Clinical and Epidemiological Characteristics of Scleroderma in Children of the Samara Region: a Single-Stage Retrospective Study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-8825-9815</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богомолова</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogomolova</surname><given-names>Juliya S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Богомолова Юлия Сергеевна - аспирант 1-го года обучения кафедры факультетской педиатрии, ассистент кафедры факультетской педиатрии.</p><p>443099, Самара, ул. Чапаевская, д. 89, тел.: +7 (996) 623-57-94</p></bio><bio xml:lang="en"><p>Julia S. Bogomolova - MD.</p><p>89, Chapaevskaya Str., Samara, 443099</p></bio><email xlink:type="simple">Julikvor26@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6078-2361</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Санталова</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Santalova</surname><given-names>Galina V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санталова Галина Владимировна - д.м.н., профессор.</p><p>Самара</p></bio><bio xml:lang="en"><p>Galina V. Santalova - MD, PhD, Professor.</p><p>Samara</p></bio><email xlink:type="simple">galina.santalova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Самарский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Samara State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>05</month><year>2025</year></pub-date><volume>22</volume><issue>2</issue><fpage>129</fpage><lpage>134</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Богомолова Ю.С., Санталова Г.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Богомолова Ю.С., Санталова Г.В.</copyright-holder><copyright-holder xml:lang="en">Bogomolova J.S., Santalova G.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pedpharma.ru/jour/article/view/2597">https://www.pedpharma.ru/jour/article/view/2597</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Ювенильная склеродермия представляет собой аутоиммунное заболевание соединительной ткани у детей разного возраста. В настоящее время нет структурированных сведений о течении данного заболевания у детей Самарской области, что затрудняет регулярное наблюдение и своевременную коррекцию терапии заболевания.</p><p>Цель исследования — создание областного регистра, а также проведение клинико-эпидемиологического анализа склеродермии у детей Самарской области за 2018–2023 гг.</p></sec><sec><title>Методы</title><p>Методы. Проведено одномоментное ретроспективное исследование в период с 2018 по 2023 г., в которое входили больные области, пролеченные в Самарском областном клиническом кардиологическом диспансере им. В.П. Полякова, в отделении детской кардиохирургии и кардиоревматологии с диагнозом «склеродермия» — 75 человек.</p></sec><sec><title>Результаты</title><p>Результаты. Отмечается рост распространенности ювенильной склеродермии среди детей (0–17 лет) за период 2018–2023 гг. в 1,3 раза. В 13% случаев пациентам устанавливался неверный диагноз, что, вероятно, связано с многообразием и неспецифичностью клинической картины ювенильной склеродермии. По результатам исследования можно отметить длительный диагностический поиск — более двух лет потребовалось для постановки верного диагноза у 17,3%, что, вероятнее всего, связано с отсутствием междисциплинарного подхода к ведению ювенильной склеродермии, а также с поздним обращением родителей к врачу. Осложненное течение системной склеродермии встречалось в 1,3% случаев и характеризовалось такими сосудистыми нарушениями, как ногтевой остеолиз дистальных фаланг, что было связано с ошибочной диагностикой на амбулаторном этапе и запоздалым направлением на консультацию ревматолога.</p></sec><sec><title>Заключение</title><p>Заключение. Проведенное исследование позволяет сделать вывод о целесообразности создания регионального регистра детей со склеродермией, анализ которого поможет педиатрам, ревматологам как амбулаторного, так и стационарного звена вовремя реагировать на имеющиеся отклонения в диагностике и терапии склеродермии и оптимизировать подходы к ведению больных данного профиля. Ограничением представленного исследования является небольшое количество детей (n = 75). Также можно предположить, что в исследование вошли не все дети региона, страдающие склеродермией, учитывая отсутствие регистра, что значительно затрудняет оценку течения заболевания.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Juvenile scleroderma is an autoimmune disease of connective tissue in children of different ages. Currently, there is no structured information about the course of this disease in children of The Samara Region, which makes it difficult to regularly monitor and timely correct the treatment of the disease.</p><p>The aim of the study is to create a regional registry, as well as to conduct a clinical and epidemiological analysis of scleroderma in children in the Samara region for 2018–2023. Methods. A single-stage retrospective study was conducted in the period from 2018 to 2023, which included 75 patients treated at the V.P. Polyakov Samara Regional Clinical Cardiology Dispensary, in the Department of Pediatric Cardiac Surgery and Cardiorheumatology with a diagnosis of scleroderma.</p></sec><sec><title>Results</title><p>Results. There has been a 1.3-fold increase in the prevalence of juvenile scleroderma among children (0–17 years old) over the period 2018–2023. In 13% of cases, patients were misdiagnosed, which is probably due to the diversity and non-specificity of the clinical picture of juvenile scleroderma. According to the results of the study, a long diagnostic search can be noted — it took more than two years for 17.3% to make a correct diagnosis, which is most likely due to the lack of an interdisciplinary approach to the management of juvenile scleroderma, as well as the late treatment of parents by a doctor. The complicated course of systemic scleroderma occurred in 1.3% of cases and was characterized by vascular disorders such as nail osteolysis of the distal phalanges, which was associated with an erroneous diagnosis at the outpatient stage and a delayed referral to a rheumatologist.</p></sec><sec><title>Conclusion</title><p>Conclusion. The conducted research allows us to conclude that it is advisable to create a local registry of children with scleroderma, the analysis of which will help pediatricians and rheumatologists of both outpatient and inpatient levels to respond in time to existing deviations in the diagnosis and therapy of scleroderma and optimize approaches to the management of patients with this profile. The limitation of the presented study is the small number of children (n = 75). It can also be assumed that the study did not include all children in the region suffering from scleroderma, given the lack of a registry, which makes it much more difficult to assess the course of the disease.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ювенильная склеродермия</kwd><kwd>эпидемиология склеродермии</kwd><kwd>дети</kwd></kwd-group><kwd-group xml:lang="en"><kwd>juvenile scleroderma</kwd><kwd>epidemiology of scleroderma</kwd><kwd>children</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Отсутствует</funding-statement><funding-statement xml:lang="en">Not specified</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Детская ревматология: руководство для врачей / под ред. А.А. Баранов, Л.К. Баженова. — М.: Медицина; 2002. — С. 138–178.</mixed-citation><mixed-citation xml:lang="en">Detskaya revmatologiya: A guide for doctors. Baranov AA, Bazhenova LK, eds. Moscow: Medicine; 2002. pp. 138–178. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Севостьянов В.К., Лотоцкая П.С., Балашов С.Л. и др. Клинико-эпидемиологический анализ юношеской системной склеродермии по данным московского регистра детей с ревматическими заболеваниями // Проблемы стандартизации в здравоохранении. — 2022. — № 5-6. — С. 49-58. — doi: https://doi.org/10.26347/1607-2502202205-06049-058</mixed-citation><mixed-citation xml:lang="en">Sevostyanov VK, Lototslaya PS, Balashov SL, et al. Clinical and epidemiological analysis of juvenile systemic scleroderma according to the Moscow register of children with rheumatic diseases. Health Care Standardization Problems. 2022;(5-6):49–58. (In Russ). doi: https://doi.org/10.26347/1607-2502202201-02053-058]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rossato M, Affandi AJ, Thordardottir S, et al. Association of MicroRNA-618 Expression with Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis. Arthritis Rheumatol. 2017;69(9):1891–1902. doi: https://doi.org/10.1002/art.40163</mixed-citation><mixed-citation xml:lang="en">Rossato M, Affandi AJ, Thordardottir S, et al. Association of MicroRNA-618 Expression with Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis. Arthritis Rheumatol. 2017;69(9):1891–1902. doi: https://doi.org/10.1002/art.40163</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">De Martinis M, Ciccarelli F, Sirufo MM, Ginaldi L. An overview of environmental risk factors in systemic sclerosis. Expert Rev Clin Immunol. 2016;12(4):465–478. doi: https://doi.org/10.1586/1744666X.2016.1125782</mixed-citation><mixed-citation xml:lang="en">De Martinis M, Ciccarelli F, Sirufo MM, Ginaldi L. An overview of environmental risk factors in systemic sclerosis. Expert Rev Clin Immunol. 2016;12(4):465–478. doi: https://doi.org/10.1586/1744666X.2016.1125782</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральные клинические рекомендации по ведению больных локализованной склеродермией / Российское общество дерматовенерологов и косметологов. — М.; 2015.</mixed-citation><mixed-citation xml:lang="en">Federal’nye klinicheskie rekomendatsii po vedeniyu bol’nykh lokalizovannoi sklerodermiei. Russian Society of Dermatovenerologists and Cosmetologists. Moscow; 2015. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025;84(1):29–40. doi: https://doi.org/10.1136/ard-2024-226430</mixed-citation><mixed-citation xml:lang="en">Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025;84(1):29–40. doi: https://doi.org/10.1136/ard-2024-226430</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Suliman YA, Distler O. Novel aspects in the pathophysiology of peripheral vasculopathy in systemic sclerosis. Curr Rheumatol Rev. 2013;9(4):237–244. doi: https://doi.org/10.2174/157339710904140417123932</mixed-citation><mixed-citation xml:lang="en">Suliman YA, Distler O. Novel aspects in the pathophysiology of peripheral vasculopathy in systemic sclerosis. Curr Rheumatol Rev. 2013;9(4):237–244. doi: https://doi.org/10.2174/157339710904140417123932</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2002;27(4):419–427. doi: https://doi.org/10.1165/rcmb.2002-0009OC</mixed-citation><mixed-citation xml:lang="en">Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2002;27(4):419–427. doi: https://doi.org/10.1165/rcmb.2002-0009OC</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rosendahl AH, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022;38(3):187–195. doi: https://doi.org/10.1002/kjm2.12505</mixed-citation><mixed-citation xml:lang="en">Rosendahl AH, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022;38(3):187–195. doi: https://doi.org/10.1002/kjm2.12505</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Проект федеральных клинических рекомендаций по ведению детей с системным склерозом / Российское общество детских ревматологов. — М.; 2021.</mixed-citation><mixed-citation xml:lang="en">Proekt federal’nykh klinicheskikh rekomendatsii po vedeniyu detei s sistemnym sklerozom. Russian Society of Pediatric Rheumatologists. Moscow; 2021. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zulian F, Martini G. Childhood systemic sclerosis. Curr Opin Rheumatol. 2007;19(6):592–597. doi: https://doi.org/10.1097/BOR.0b013e3282f01625</mixed-citation><mixed-citation xml:lang="en">Zulian F, Martini G. Childhood systemic sclerosis. Curr Opin Rheumatol. 2007;19(6):592–597. doi: https://doi.org/10.1097/BOR.0b013e3282f01625</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Территориальный орган Федеральной службы государственной статистики по Самарской области: официальный сайт. Доступно по: https://63.rosstat.gov.ru. Ссылка активна на 09.04.2025.</mixed-citation><mixed-citation xml:lang="en">Territorial body of the Federal State Statistics Service for the Samara Region: Official website. (In Russ). Доступно по: https://63.rosstat.gov.ru. Ссылка активна на 09.04.2025.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Самарская область — сколько населения в 1991–2020 году? // Численность населения РФ: официальный сайт. Доступно по: https://численность-населения.рф/самарская-область. Ссылка активна на 09.04.2025.</mixed-citation><mixed-citation xml:lang="en">Samara Oblast — what is the population in 1991–2020? In: Population of the Russian Federation: Official website. (In Russ).] Доступно по: https://численность-населения.рф/самарская-область. Ссылка активна на 09.04.2025.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández-Codina A, Walker KM, Pope JE. Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol. 2018;70(11):1820–1828. doi: https://doi.org/10.1002/art.40560</mixed-citation><mixed-citation xml:lang="en">Fernández-Codina A, Walker KM, Pope JE. Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol. 2018;70(11):1820–1828. doi: https://doi.org/10.1002/art.40560</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Раупов Р.К., Имельбаев А.И., Костик М.М. Ювенильная локализованная склеродермия с позиции детского ревматолога. Вопросы диагностики // Вопросы современной педиатрии. — 2020. — Т. 19. — № 2. — С. 150–161. — doi: https://doi.org/10.15690/vsp.v19i2.2109</mixed-citation><mixed-citation xml:lang="en">Raupov RK, Imelbaev AI, Kostik MM. Juvenile Localized Scleroderma from the Perspective of Pediatric Rheumatologist. Aspects of Diagnostics. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(2):150–161. (In Russ). doi: https://doi.org/10.15690/vsp.v19i2.2109</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364–72. doi: https://doi.org/10.1093/rheumatology/35.4.364</mixed-citation><mixed-citation xml:lang="en">van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364–72. doi: https://doi.org/10.1093/rheumatology/35.4.364</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351–1358. doi: https://doi.org/10.1002/1529-0131(200106)44:6&lt;1351</mixed-citation><mixed-citation xml:lang="en">Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351–1358. doi: https://doi.org/10.1002/1529-0131(200106)44:6&lt;1351</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Smith V, Herrick AL, Ingegnoli F, et al. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud’s phenomenon and systemic sclerosis. Autoimmun Rev. 2020;19(3):102458. doi: https://doi.org/10.1016/j.aut-rev.2020.102458</mixed-citation><mixed-citation xml:lang="en">Smith V, Herrick AL, Ingegnoli F, et al. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud’s phenomenon and systemic sclerosis. Autoimmun Rev. 2020;19(3):102458. doi: https://doi.org/10.1016/j.aut-rev.2020.102458</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Marrani E, Foeldvari I, Lopez JA, et al. Comparing ultraviolet light A photo(chemo)therapy with Methotrexate protocol in childhood localized scleroderma: Evidence from systematic review and meta-analysis approach. Semin Arthritis Rheum. 2018;48(3):495–503. doi: https://doi.org/10.1016/j.semarthrit.2018.03.003</mixed-citation><mixed-citation xml:lang="en">Marrani E, Foeldvari I, Lopez JA, et al. Comparing ultraviolet light A photo(chemo)therapy with Methotrexate protocol in childhood localized scleroderma: Evidence from systematic review and meta-analysis approach. Semin Arthritis Rheum. 2018;48(3):495–503. doi: https://doi.org/10.1016/j.semarthrit.2018.03.003</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int. 2012;32(3):645–653. doi: https://doi.org/10.1007/s00296-010-1697-6</mixed-citation><mixed-citation xml:lang="en">Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int. 2012;32(3):645–653. doi: https://doi.org/10.1007/s00296-010-1697-6</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar AB, Blixt EK, Drage LA, et al. Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996–2013. J Am Acad Dermatol. 2019;80(6):1658–1663. doi: https://doi.org/10.1016/j.jaad.2019.01.040</mixed-citation><mixed-citation xml:lang="en">Kumar AB, Blixt EK, Drage LA, et al. Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996–2013. J Am Acad Dermatol. 2019;80(6):1658–1663. doi: https://doi.org/10.1016/j.jaad.2019.01.040</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
